US 12,168,694 B2
Anti-human CD45RC antibodies and uses thereof
Carole Guillonneau, La Chevrolière (FR); and Ignacio Anegon, Nantes (FR)
Assigned to INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); NANTES UNIVERSITE, Nantes (FR); and CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, Nantes (FR)
Appl. No. 17/277,511
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); UNIVERSITÉ DE NANTES, Nantes (FR); and CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES, Nantes (FR)
PCT Filed Sep. 20, 2019, PCT No. PCT/EP2019/075374
§ 371(c)(1), (2) Date Mar. 18, 2021,
PCT Pub. No. WO2020/058495, PCT Pub. Date Mar. 26, 2020.
Claims priority of application No. 18306230 (EP), filed on Sep. 21, 2018.
Prior Publication US 2022/0033500 A1, Feb. 3, 2022
Int. Cl. A61P 37/06 (2006.01); C07K 16/28 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/289 (2013.01) [A61P 37/06 (2018.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 20 Claims
 
1. An isolated anti-human CD45RC antibody or binding fragment thereof, wherein said antibody or binding fragment thereof comprises:
(a) a heavy chain variable region (HCVR) which comprises the following three complementary-determining regions (CDRs):
(i) VH-CDR1 of sequence SEQ ID NO: 1;
(ii) VH-CDR2 with a sequence selected from the group consisting of sequences SEQ ID NOs: 4, 5, 6, 7, 8, 9, 10, 11, 100, 116, 117, 118 and 119; and
(iii) VH-CDR3 of sequence SEQ ID NO: 3; and
(b) a light chain variable region (LCVR) which comprises the following three CDRs:
(i) VL-CDR1 with a sequence selected from the group consisting of sequences SEQ ID NO: 15 (SASSSVS-X-YMH) and SEQ ID NO: 18 (RASSSVS-X-YMH), wherein X is absent or is selected from the group consisting of Asn (N), Ser(S) and Gly (G);
(ii) VL-CDR2 with a sequence selected from the group consisting of sequences SEQ ID NOs: 16, 19, 20, 22, 111, 120 and 127; and
(iii) VL-CDR3 with a sequence selected from the group consisting of sequences SEQ ID NOs: 17 and 21.